Barbra Keck Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Barbra Keck DCTH stock SEC Form 4 insiders trading

Barbra has made over 3 trades of the Delcath Systems stock since 2009, according to the Form 4 filled with the SEC. Most recently Barbra bought 7,399 units of DCTH stock worth $12,948 on 28 September 2018.

The largest trade Barbra's ever made was buying 7,399 units of Delcath Systems stock on 28 September 2018 worth over $12,948. On average, Barbra trades about 472 units every 190 days since 2009. As of 28 September 2018 Barbra still owns at least 7,500 units of Delcath Systems stock.

You can see the complete history of Barbra Keck stock trades at the bottom of the page.

What's Barbra Keck's mailing address?

Barbra's mailing address filed with the SEC is C/O DELCATH SYSTEMS, INC.,, 1633 BROADWAY, SUITE 22C, NEW YORK, NY, 10019.

Insiders trading at Delcath Systems

Over the last 5 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,192,084 units worth $8,856,388 . The most active insiders traders include Marco Taglietti, Gerard J Michel et Advisors, Inc. Rosalind. On average, Delcath Systems executives and independent directors trade stock every 25 days with the average trade being worth of $242,307. The most recent stock trade was executed by Gil Aharon on 19 March 2024, trading 26,882 units of DCTH stock currently worth $100,001.

What does Delcath Systems do?

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Delcath Systems executives and stock owners

Delcath Systems executives and other stock owners filed with the SEC include:

• John Purpura,
  Chief Operating Officer, Executive Vice President - Global Head of Operations
• John Purpura M.S.,
  Chief Operating Officer
• Gerard J. Michel,
  CEO & Director
• Roger Stoll,
  Non-Executive Independent Chairman of the Board
• John Sylvester,
  Independent Director
• Steven Salamon,
  Independent Director
• Elizabeth Czerepak,
  Independent Director
• Gilad Aharon,
  Independent Director
• Christine Padula,
  Interim Principal Accounting Officer
• Gerard Michel,
  Chief Executive Officer, Director
• Dr. Johnny John M.D.,
  Sr. VP Clinical Devel. & Medical Affairs
• Robin Wagge,
  Sr. VP of Rubenstein Associates
• Thomas Johnson,
  Sr. Director of Corp. Communications
• Bridget A Martell,
  
• Gil Aharon,
  
• Advisors, Inc. Rosalind,
  Director
• Anthony Dias,
  VP FINANCE
• Advisors, Inc.Aharon Gil Sa...,
  
• Johnny John,
  SVP CLINICAL DEV & MED AFFAIRS
• Jennifer K. Simpson,
  President and CEO
• William Dodge Rueckert,
  Director
• Marco Taglietti,
  Director
• Barbra Keck,
  Chief Financial Officer
• Advisors, Inc.Salamon Steve...,
  
• Martha S. Rook,
  CHIEF OPERATING OFFICER
• Vojo Vukovic,
  CHIEF MEDICAL OFFICER
• Kevin Muir,
  GM INTERVENTIONAL ONCOLOGY
• David L. Hoffman,
  GEN'L COUNSEL, CCO & SECY